Asset Details
Do you wish to reserve the book?
Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors
Do you wish to request the book?
Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors
2008
Overview
The intent of this study was to evaluate the safety and efficacy of high-activity 111In-pentetreotide in patients with neuroendocrine tumors. Thirty-two patients with pentetreotide-avid neuroendocrine tumors received therapy from August 2005 to November 2006. Fourteen (14) patients received 1 treatment and 18 patients received 2 treatments. Patients were followed an average of 12.73 months (range 1.2–24.5). Seventeen (17) patients (53%) had grade I or II hematologic toxicities, and 1 patient had grade III thrombocytopenia. One patient had grade II liver toxicity, which appeared 4 weeks after therapy and resolved on week 5. No patient had renal toxicity. Of the patients who completed 2 treatment cycles, 2 of 18 patients had partial disease regression, and 16 of 18 patients with previously progressive disseminated neuroendocrine disease achieved stable disease by imaging criteria. A decrease in serum tumor markers was observed in 14 of 18 patients given 2 therapies. A clinical response was achieved in 84% of the patients. Upon interim analysis, median survival was approximately 13 months (range 1.2–24.5). These results show that high-activity 111In-pentetreotide therapy is effective in patients with progressive disseminated neuroendocrine tumors.
Publisher
SAGE Publications,Mary Ann Liebert, Inc
